

For Immediate Release

For More Information:

Molly Varnau
Front Line Strategic Consulting, Inc.
650-525-1500 x.102
www.frontlinesmc.com
info@frontlinesmc.com

**DNA, PROTEIN, AND TISSUE/CELLULAR ARRAYS MARKET
EXPECTED TO REACH OVER \$1.6 BILLION BY 2008**

*Array Technology Continues to be an Indispensable Tool for Drug Discovery and
Clinical Diagnostics*

May 21, 2003, San Mateo, Calif. — The worldwide arrays market is projected to experience a 15% overall compound annual growth rate (CAGR) over the next five years as pharmaceutical and biotechnology companies seek more efficient and cost effective tools to identify drug targets. Microarray technology provides the ability to use substrate-sample complementary binding to mass-screen chemical or biological properties, allowing for the parallel analysis of thousands of genes, protein, or tissue samples on a single array. They are widely used for hybridization-based gene, protein, and tissue expression analysis, particularly when screening for potential therapeutic targets and determining reactions to toxins. While DNA arrays will continue to dominate the microarray R&D landscape with an estimated 84% market share in 2003, emerging protein arrays will likely experience exceptionally strong growth as high-throughput proteomics is more widely adopted for drug target identification and validation research.

According to Front Line's strategic market report released today, entitled **DNA, Protein, and Tissue/Cellular Arrays: Opportunities and Technical Analysis**, specific factors driving the development and growth of the arrays market include segment consolidation, standardization of array data, establishment of robust databases, and the development of clinical diagnostics. "While microarrays are advantageous in facilitating

- more -

high-throughput screening, certain challenges remain, such as accuracy and quality of data that require further attention,” says Charles Chang, analyst, strategic market reports for Front Line. The report evaluates leading technologies, their areas of therapeutic application, and technical ranking while providing in-depth analysis of key companies and strategic options for future success and profitability.

About Front Line

Headquartered in San Mateo, Calif., Front Line is a leader in strategic consulting and market analysis for the Life Sciences industries, offering strategic business intelligence through exclusive consulting engagements and comprehensive strategic market reports of key therapeutic and technology areas. Front Line was founded in 1992 and specializes in combining diligent research methodology with intelligent strategic planning for their pharmaceutical and biotechnology customers. www.frontlinesmc.com

###